Derek DiRocco
Director/Miembro de la Junta en MINERALYS THERAPEUTICS, INC. .
Fortuna: 165 800 $ al 30/04/2024
Cargos activos de Derek DiRocco
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
89BIO, INC. | Director/Miembro de la Junta | 01/04/2018 | - |
Independent Dir/Board Member | 01/04/2018 | - | |
WEREWOLF THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/12/2020 | - |
Independent Dir/Board Member | 01/12/2020 | - | |
ACRIVON THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/11/2021 | - |
Independent Dir/Board Member | 01/11/2021 | - | |
MINERALYS THERAPEUTICS, INC. | Director/Miembro de la Junta | 08/05/2022 | - |
Independent Dir/Board Member | 08/05/2022 | - | |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Analyst-Equity | - | - |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Director/Miembro de la Junta | - | - |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Inversor de Capital Privado | 01/12/2017 | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | - | - |
Suzhou Connect Biopharma Co. Ltd.
Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Director/Miembro de la Junta | - | - |
Historial de carrera de Derek DiRocco
Antiguos cargos conocidos de Derek DiRocco.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░ ░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formación de Derek DiRocco.
University of Washington | Doctorate Degree |
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 13 |
Reino Unido | 3 |
China | 2 |
Operativa
Director/Board Member | 13 |
Independent Dir/Board Member | 8 |
Analyst-Equity | 1 |
Sectorial
Health Technology | 14 |
Finance | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 10 |
---|---|
Health Technology | |
89BIO, INC. | Health Technology |
WEREWOLF THERAPEUTICS, INC. | Health Technology |
ITEOS THERAPEUTICS, INC. | Health Technology |
ACRIVON THERAPEUTICS, INC. | Health Technology |
DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
CONNECT BIOPHARMA HOLDINGS LIMITED | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
MINERALYS THERAPEUTICS, INC. | Health Technology |
CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
Empresas privadas | 5 |
---|---|
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Finance |
Suzhou Connect Biopharma Co. Ltd.
Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Health Technology |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
- Bolsa de valores
- Insiders
- Derek DiRocco
- Experiencia